A Systematic Statistical Approach to Evaluating Evidence from Observational Studies
暂无分享,去创建一个
D. Madigan | M. Suchard | M. Schuemie | J. Overhage | P. Ryan | P. Stang | A. Hartzema | J. Berlin | Bill Dumouchel | Jesse A. Berlin
[1] K. Popper,et al. Conjectures and refutations;: The growth of scientific knowledge , 1972 .
[2] K. Popper,et al. Conjectures and refutations;: The growth of scientific knowledge , 1972 .
[3] C. Mackenzie,et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.
[4] A. Hartzema,et al. Pharmacoepidemiology: An Introduction , 1991 .
[5] C. Tilquin,et al. Risk Adjustment in Outcome Assessment: the Charlson Comorbidity Index , 1993, Methods of Information in Medicine.
[6] J. Gold,et al. Validation of a combined comorbidity index. , 1994, Journal of clinical epidemiology.
[7] D. Labarthe,et al. An assessment of the validity of ICD Code 410 to identify hospital admissions for myocardial infarction: The Corpus Christi Heart Project. , 1996, International journal of epidemiology.
[8] A Bouckaert,et al. Practical considerations on the use of the Charlson comorbidity index with administrative data bases. , 1996, Journal of clinical epidemiology.
[9] A. Walker. Confounding by indication. , 1996, Epidemiology.
[10] Donald Rubin,et al. Estimating Causal Effects from Large Data Sets Using Propensity Scores , 1997, Annals of Internal Medicine.
[11] M. Cleves,et al. Evaluation of two competing methods for calculating Charlson's comorbidity index when analyzing short-term mortality using administrative data. , 1997, Journal of clinical epidemiology.
[12] H Tunstall-Pedoe,et al. Validity of ICD code 410 to identify hospital admission for myocardial infarction. , 1997, International Journal of Epidemiology.
[13] R Platt,et al. Assessment of asthma using automated and full-text medical records. , 1997, The Journal of asthma : official journal of the Association for the Care of Asthma.
[14] S. Gutthann,et al. Use of the UK General Practice Research Database for pharmacoepidemiology. , 1998, British journal of clinical pharmacology.
[15] C. Weinberg,et al. Use and misuse of population attributable fractions. , 1998, American journal of public health.
[16] M. Szklo,et al. Epidemiology: Beyond the Basics , 1999 .
[17] N. Christakis,et al. The performance of different lookback periods and sources of information for Charlson comorbidity adjustment in Medicare claims. , 1999, Medical care.
[18] B. Strom,et al. Data validity issues in using claims data , 2001, Pharmacoepidemiology and drug safety.
[19] M Maclure,et al. Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data. , 2001, American journal of epidemiology.
[20] D J Graham,et al. The role of databases in drug postmarketing surveillance , 2001, Pharmacoepidemiology and drug safety.
[21] P. De Wals,et al. A Prospective Evaluation of the Charlson Comorbidity Index for Use in Long‐Term Care Patients , 2002, Journal of the American Geriatrics Society.
[22] K. Rothman. Epidemiology: An Introduction , 2002 .
[23] D. Fife,et al. The impact of wording in “Dear doctor” letters and in black box labels , 2002, Clinical pharmacology and therapeutics.
[24] F. Sacks,et al. A propensity score-matched cohort study of the effect of statins, mainly fluvastatin, on the occurrence of acute myocardial infarction. , 2003, The American journal of cardiology.
[25] W. Ray,et al. Evaluating medication effects outside of clinical trials: new-user designs. , 2003, American journal of epidemiology.
[26] Patrick C Waller,et al. A model for the future conduct of pharmacovigilance , 2003, Pharmacoepidemiology and drug safety.
[27] N. Jewell. Statistics for Epidemiology , 2003 .
[28] R. Tamblyn,et al. Validation of diagnostic codes within medical services claims. , 2004, Journal of clinical epidemiology.
[29] T. Lancaster,et al. Instrumental variables and inverse probability weighting for causal inference from longitudinal observational studies , 2004, Statistical methods in medical research.
[30] Hude Quan,et al. Comparison of the Elixhauser and Charlson/Deyo Methods of Comorbidity Measurement in Administrative Data , 2004, Medical care.
[31] G. Guyatt,et al. Grading quality of evidence and strength of recommendations , 2004, BMJ : British Medical Journal.
[32] Colleen Brensinger,et al. Agreement between GPRD smoking data: a survey of general practitioners and a population‐based survey , 2004, Pharmacoepidemiology and drug safety.
[33] Peter J Pronovost,et al. A systematic review of the Charlson comorbidity index using Canadian administrative databases: a perspective on risk adjustment in critical care research. , 2005, Journal of critical care.
[34] J. Tisdale,et al. Drug-Induced Diseases: Prevention, Detection, and Management , 2005 .
[35] A. M. Walker,et al. An application of propensity score matching using claims data , 2005, Pharmacoepidemiology and drug safety.
[36] H. Quan,et al. Coding Algorithms for Defining Comorbidities in ICD-9-CM and ICD-10 Administrative Data , 2005, Medical care.
[37] J. Ioannidis. Why Most Published Research Findings Are False , 2005, PLoS medicine.
[38] Sebastian Schneeweiss,et al. Adjusting for Unmeasured Confounders in Pharmacoepidemiologic Claims Data Using External Information: The Example of COX2 Inhibitors and Myocardial Infarction , 2005, Epidemiology.
[39] J. Avorn,et al. A review of uses of health care utilization databases for epidemiologic research on therapeutics. , 2005, Journal of clinical epidemiology.
[40] Peter C Austin,et al. Comparison of Coding of Heart Failure and Comorbidities in Administrative and Clinical Data for Use in Outcomes Research , 2005, Medical care.
[41] Patrick Musonda,et al. Tutorial in biostatistics: the self‐controlled case series method , 2006, Statistics in medicine.
[42] Sean Hennessy,et al. Use of health care databases in pharmacoepidemiology. , 2006, Basic & clinical pharmacology & toxicology.
[43] J. Farley,et al. A comparison of comorbidity measurements to predict healthcare expenditures. , 2006, The American journal of managed care.
[44] Tom Fawcett,et al. An introduction to ROC analysis , 2006, Pattern Recognit. Lett..
[45] S. Schneeweiss. Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics , 2006, Pharmacoepidemiology and drug safety.
[46] Lawrence So,et al. ICD-10 coding algorithms for defining comorbidities of acute myocardial infarction , 2006, BMC Health Services Research.
[47] J. Avorn,et al. Increasing Levels of Restriction in Pharmacoepidemiologic Database Studies of Elderly and Comparison With Randomized Trial Results , 2007, Medical care.
[48] Samy Suissa,et al. Primer: administrative health databases in observational studies of drug effects—advantages and disadvantages , 2007, Nature Clinical Practice Rheumatology.
[49] J. Avorn,et al. Adjustments for Unmeasured Confounders in Pharmacoepidemiologic Database Studies Using External Information , 2007, Medical care.
[50] Hassan Fouayzi,et al. Validity of gout diagnoses in administrative data. , 2007, Arthritis and rheumatism.
[51] Charles E. Leonard,et al. Quality of Medicaid and Medicare Data Obtained Through Centers for Medicare and Medicaid Services (CMS) , 2007, Medical care.
[52] Samy Suissa,et al. Immortal time bias in observational studies of drug effects , 2007, Pharmacoepidemiology and drug safety.
[53] T. Kurth,et al. Use of Propensity Score Technique to Account for Exposure-Related Covariates: An Example and Lesson , 2007, Medical care.
[54] W. Bilker,et al. Validation studies of the health improvement network (THIN) database for pharmacoepidemiology research , 2007, Pharmacoepidemiology and drug safety.
[55] S. Schneeweiss,et al. Developments in Post‐marketing Comparative Effectiveness Research , 2007, Clinical pharmacology and therapeutics.
[56] Harold I Feldman,et al. Diagnostic E-codes for commonly used, narrow therapeutic index medications poorly predict adverse drug events. , 2008, Journal of clinical epidemiology.
[57] Donald R. Miller,et al. Angioedema Incidence in US Veterans Initiating Angiotensin-Converting Enzyme Inhibitors , 2008, Hypertension.
[58] Jordi Castellsague,et al. Positive predictive value of ICD‐9 codes 410 and 411 in the identification of cases of acute coronary syndromes in the Saskatchewan Hospital automated database , 2008, Pharmacoepidemiology and drug safety.
[59] Jesse A Berlin,et al. Adverse event detection in drug development: recommendations and obligations beyond phase 3. , 2008, American journal of public health.
[60] S. Suissa. Practice of Epidemiology Immortal Time Bias in Pharmacoepidemiology , 2008 .
[61] K. Rothman,et al. Exclusion of immortal person‐time , 2008, Pharmacoepidemiology and drug safety.
[62] John D Seeger,et al. Aprotinin during coronary-artery bypass grafting and risk of death. , 2008, The New England journal of medicine.
[63] Bing Li,et al. Risk adjustment performance of Charlson and Elixhauser comorbidities in ICD-9 and ICD-10 administrative databases , 2008, BMC health services research.
[64] Abraham G. Hartzema,et al. Pharmacoepidemiology and therapeutic risk management , 2008 .
[65] J. Avorn,et al. High-dimensional Propensity Score Adjustment in Studies of Treatment Effects Using Health Care Claims Data , 2009, Epidemiology.
[66] Jim Bellows,et al. Preventing myocardial infarction and stroke with a simplified bundle of cardioprotective medications. , 2009, The American journal of managed care.
[67] M Alan Brookhart,et al. Instrumental variables I: instrumental variables exploit natural variation in nonexperimental data to estimate causal relationships. , 2009, Journal of clinical epidemiology.
[68] Mark Lunt,et al. Different Methods of Balancing Covariates Leading to Different Effect Estimates in the Presence of Effect Modification , 2009, American journal of epidemiology.
[69] S. Cole,et al. Overadjustment Bias and Unnecessary Adjustment in Epidemiologic Studies , 2009, Epidemiology.
[70] J. Katz,et al. Comparative gastrointestinal safety of weekly oral bisphosphonates , 2009, Osteoporosis International.
[71] A. Pariente,et al. Data mining on electronic health record databases for signal detection in pharmacovigilance: which events to monitor? , 2009, Pharmacoepidemiology and drug safety.
[72] J. Rassen,et al. Confounding Control in Healthcare Database Research: Challenges and Potential Approaches , 2010, Medical care.
[73] J. Rassen,et al. Safety and effectiveness of bivalirudin in routine care of patients undergoing percutaneous coronary intervention. , 2010, European heart journal.
[74] Sebastian Schneeweiss,et al. Instrumental variable methods in comparative safety and effectiveness research , 2010, Pharmacoepidemiology and drug safety.
[75] Timothy L Lash,et al. A most stubborn bias: no adjustment method fully resolves confounding by indication in observational studies. , 2010, Journal of clinical epidemiology.
[76] Charles E. Leonard,et al. Validation of diagnostic codes for outpatient‐originating sudden cardiac death and ventricular arrhythmia in Medicaid and Medicare claims data , 2009, Pharmacoepidemiology and drug safety.
[77] Sebastian Schneeweiss,et al. A basic study design for expedited safety signal evaluation based on electronic healthcare data , 2010, Pharmacoepidemiology and drug safety.
[78] Sebastian Schneeweiss,et al. Validation of claims‐based diagnostic and procedure codes for cardiovascular and gastrointestinal serious adverse events in a commercially‐insured population , 2010, Pharmacoepidemiology and drug safety.
[79] J. Overhage,et al. Advancing the Science for Active Surveillance: Rationale and Design for the Observational Medical Outcomes Partnership , 2010, Annals of Internal Medicine.
[80] S. Cole,et al. Illustrating bias due to conditioning on a collider. , 2010, International journal of epidemiology.
[81] Patrick B Ryan,et al. Design and validation of a data simulation model for longitudinal healthcare data. , 2011, AMIA ... Annual Symposium proceedings. AMIA Symposium.
[82] Samy Suissa,et al. The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study , 2012, BMJ : British Medical Journal.
[83] Timothy L. Lash,et al. Comprar Modern Epidemiology | Timothy L. Lash | 9781451190052 | Lippincott Williams & Wilkins , 2012 .
[84] Malcolm Maclure,et al. Design considerations in an active medical product safety monitoring system , 2012, Pharmacoepidemiology and drug safety.
[85] C Michael Stein,et al. Azithromycin and the risk of cardiovascular death. , 2012, The New England journal of medicine.
[86] Patrick B. Ryan,et al. Validation of a common data model for active safety surveillance research , 2012, J. Am. Medical Informatics Assoc..
[87] D. Madigan,et al. Empirical assessment of methods for risk identification in healthcare data: results from the experiments of the Observational Medical Outcomes Partnership , 2012, Statistics in medicine.
[88] Martijn J. Schuemie,et al. Using Electronic Health Care Records for Drug Safety Signal Detection: A Comparative Evaluation of Statistical Methods , 2012, Medical care.
[89] M. Schuemie,et al. Defining a Reference Set to Support Methodological Research in Drug Safety , 2013, Drug Safety.
[90] Brent I. Fox,et al. How Well Do Various Health Outcome Definitions Identify Appropriate Cases in Observational Studies? , 2013, Drug Safety.
[91] William DuMouchel,et al. Interpreting observational studies: why empirical calibration is needed to correct p-values , 2013, Statistics in medicine.
[92] Confounding by Indication: Response , 2016, The American journal of sports medicine.